News

According to the company, the proceeds from the financing will be used to fund the continued clinical development of PB-272 (oral neratinib). PB-272 (oral neratinib) is an irreversible

The multidisciplinary team includes researchers from the Virginia Commonwealth University School of Medicine, together with the Mount Sinai School of Medicine in New York and the University of

The innovation fund, created in March 2008, intends to support human health research projects in Québec. The first research project is named Impact des inhibiteurs intracellulaires du DCIR

Under the collaboration deal, NCI and NHGRI will apply Horizon’s rAAV gene editing technology (GENESIS) to engineer human isogenic disease models for its researchers. In addition, X-MAN (gene

The product, whose manufacturing and packaging has been completed, will be made available through Marisol Therapeutics for patient usage. The second Cannabis Science Brand extract-based formulation contains the

Perifosine is an oral anticancer treatment that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. The drug is in two Phase 3 programs for the treatment of

Alogliptin is a selective dipeptidyl peptidase IV inhibitor (DPP-4i) which is being evaluated in the US to treat type 2 diabetes as an adjunct to diet and exercise.

By adopting IBM Initiate, DB2, Cognos, and WebSphere software into its MEDxConnect platform, Compressus intends to look into the issue of interoperability. MEDxConnect provides an easy way to

Intermezzo is available in doses of 1.75 mg and 3.5 mg as a sublingual tablet that contains a bicarbonate-carbonate buffer. The approval is backed by two placebo-controlled studies